文献速递关节外科骨质疏松与代谢性骨病

糖皮质激素使用对股骨头坏死发生与进展的影响:全国性巢式病例对照研究

Effect of Corticosteroid Use on the Occurrence and Progression of Osteonecrosis of the Femoral Head: A Nationwide Nested Case-Control Study.
PubMed 文献 · J Arthroplasty · 2024-06-01

韩国全国性巢式病例对照研究(2002至2019年)纳入3500例股骨头坏死(ONFH)患者并按出生年、性别和随访时长1:5匹配对照,发现全身性糖皮质激素累计剂量≥1800 mg与ONFH发生风险显著相关,但血脂谱、糖皮质激素处方及累计剂量未影响进展至全髋关节置换术(THA)。

要点

  • 全身性糖皮质激素累计剂量≥1800 mg与ONFH发生风险显著增加相关。
  • 血脂谱、糖皮质激素处方及累计剂量未影响ONFH进展至THA。
  • ONFH患者家庭收入较低,糖尿病、高血压、血脂异常及大量饮酒更多见。

核心结论

  • 累计泼尼松龙用量≥1800 mg时ONFH风险迅速增加。
  • 口服或大剂量静脉糖皮质激素使用及累计剂量未影响ONFH预后。
  • ONFH的发生与预后为复杂多因素过程,需进一步研究。

研究设计与样本

  • 全国性巢式病例对照研究,数据来自韩国国民健康保险服务体检队列(2002至2019年)。
  • 定义ONFH患者3500例,按出生年、性别和随访时长1:5匹配对照。
  • 在ONFH患者中分析进展至THA的危险因素。

主要发现

  • 与对照组相比,ONFH患者家庭收入较低,糖尿病、高血压、血脂异常及大量饮酒(每周饮酒超过3至7杯)更多。
  • 全身性糖皮质激素使用(≥1800 mg)与ONFH发生风险增加显著相关。
  • 血脂谱、糖皮质激素处方及糖皮质激素累计剂量未影响进展至THA。

关键数值与推荐

  • 全身性糖皮质激素累计剂量≥1800 mg与ONFH发生风险显著增加相关。
  • 累计泼尼松龙用量≥1800 mg时ONFH风险迅速增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出ONFH的发生与预后为复杂多因素过程,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although it is very well known that corticosteroids cause osteonecrosis of the femoral head (ONFH), it is unclear as to which patients develop ONFH. Additionally, there are no studies on the association between corticosteroid use and femoral head collapse in ONFH patients. We aimed to investigate the association between corticosteroid use and the risk of ONFH among the general population and what factors affect ONFH occurrence. Additionally, we aimed to demonstrate which factors affect femoral head collapse and total hip arthroplasty (THA) after ONFH occurrence. METHODS: A nationwide, nested case-control study was conducted with data from the National Health Insurance Service Physical Health Examination Cohort (2002 to 2019) in the Republic of Korea. We defined ONFH (N = 3,500) using diagnosis and treatment codes. Patients who had ONFH were matched 1:5 to form a control group based on the variables of birth year, sex, and follow-up duration. Additionally, in patients who have ONFH, we looked for risk factors for progression to THA. RESULTS: Compared with the control group, ONFH patients had a low household income and had more diabetes, hypertension, dyslipidemia, and heavy alcohol use (drinking more than 3 to 7 drinks per week). Systemic corticosteroid use (≥1,800 mg) was significantly associated with an increased risk of ONFH incidence. However, lipid profiles, corticosteroid prescription, and cumulative doses of corticosteroid did not affect the progression to THA. CONCLUSIONS: The ONFH risk increased rapidly when cumulative prednisolone use was ≥1,800 mg. However, oral or high-dose intravenous corticosteroid use and cumulative dose did not affect the prognosis of ONFH. Since the occurrence and prognosis of ONFH are complex and multifactorial processes, further study is needed.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Kwon HM, Han M, Lee TS, et al. Effect of Corticosteroid Use on the Occurrence and Progression of Osteonecrosis of the Femoral Head: A Nationwide Nested Case-Control Study. J Arthroplasty. 2024. PMID: 38830431. doi:10.1016/j.arth.2024.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。